Piramal Snaps Up Peptide API Specialist Hemmo

Bolsters CDMO Business In Deal Worth More Than $100m

Piramal has announced a $106m deal to take full ownership of peptide API specialist Hemmo Pharmaceuticals, expanding its CDMO capabilities.

API Wooden Blocks Graphs
Piramal Pharma Solutions will gain peptide API capabilities from Hemmo • Source: Shutterstock

Piramal Pharma Limited has announced that it will bolster its Piramal Pharma Solutions contract development and manufacturing organization by acquiring peptide active pharmaceutical ingredient specialist Hemmo Pharmaceuticals “for an upfront consideration of INR7.75bn ($106m) and earn-outs linked to achievement of milestones.”

Noting that the acquisition, which is subject to customary regulatory closing conditions, would add peptide API development and manufacturing capabilities...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deals

Kashiv Joins Forces With MS Pharma In MENA For Omalizumab

 
• By 

Kashiv BioSciences has struck a deal with MS Pharma to market its omalizumab biosimilar rival to Xolair in the MENA region.

Civica Pairs With Fresenius Kabi To Supply Stelara Biosimilar

 
• By 

US non-profit Civica has announced a partnership with Fresenius Kabi to supply a Stelara rival, revealing pricing details for its exclusive unbranded version of Kabi’s Otulfi biosimilar that will be available from the start of next year.

Aurobindo Expects Lannett Acquisition To Pass FTC Scrutiny; Q1 US Revenue Falls

 
• By 

Aurobindo is confident its planned Lannett acquisition will pass US FTC scrutiny after an attempt to acquire Sandoz assets was called off in 2020 post a delay in approval. The deal could widen Aurobindo’s US manufacturing presence at a time when its US Q1 revenue saw a year-on-year decline.

Polpharma Biologics And Fresenius Kabi Team Up On Entyvio Biosimilar

 

Fresenius Kabi has picked up commercialization rights to Polpharma Biologics’ vedolizumab biosimilars in almost all markets. Still, the originator Takeda stands solid with no competition expected until at least 2032.

More from Business

Repurposed Generics For Rare Diseases: Janet Woodcock Proposes Shortcut

A Duke-Margolis working group is developing ideas to enable non-profit firms to seek US FDA approval for new indications for off-patent medicines. The former acting commissioner thinks citizen petitions might be the fastest route.

Kashiv Joins Forces With MS Pharma In MENA For Omalizumab

 
• By 

Kashiv BioSciences has struck a deal with MS Pharma to market its omalizumab biosimilar rival to Xolair in the MENA region.

Civica Pairs With Fresenius Kabi To Supply Stelara Biosimilar

 
• By 

US non-profit Civica has announced a partnership with Fresenius Kabi to supply a Stelara rival, revealing pricing details for its exclusive unbranded version of Kabi’s Otulfi biosimilar that will be available from the start of next year.